Vivid Dx raised $15M in a Seed round announced on July 29, 2026. Vivid Dx is an Oxford, UK-based provider of a precision diagnostics platform improving pathogen detection and antimicrobial resistance (AMR) testing.
Vivid Dx is an Oxford, UK-based provider of a precision diagnostics platform improving pathogen detection and antimicrobial resistance (AMR) testing.
Vivid Dx, based in Oxford, United Kingdom, announced $15M in Seed financing on July 29, 2026.
Participants include Jameel Investment Management Company, Oxford Science Enterprises, Cedars-Sinai Intellectual Property Co..
The company develops AI-powered software and data infrastructure to make robots used in factories work more efficiently.
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.